



# Biotech Daily

Thursday June 14, 2012

*Daily news on ASX-listed biotechnology companies*

- \* **ASX, BIOTECH DOWN: SUNSHINE HEART UP 18%; CELLMID DOWN 11%**
- \* **RESMED LAUNCHES NARVAL JAW POSITION DEVICE**
- \* **PAYMENT ENDS NUSEP, NXGEN LONGER LASTING LISTING LITIGATION**
- \* **HEALTHLINX LOSES DR STEWART WASHER, DR JOHN CHIPLIN**
- \* **LARRY KNOPF REPLACES HEARTWARE CO SEC DAVID MCINTYRE**
- \* **ATCOR TAKES CAPITAL RAISING TRADING HALT TO SUSPENSION**

## MARKET REPORT

The Australian stock market fell 0.53 percent on Thursday June 14, 2012 with the S&P ASX 200 down 21.6 points to 4,042.2 points.

Seven of the Biotech Daily Top 40 stocks were up, 15 fell, 11 traded unchanged and seven were untraded. All three Big Caps fell.

Sunshine Heart was the best, up 0.4 cents or 18.2 percent to 2.6 cents with 959,300 shares traded.

Genetic Technologies climbed 9.5 percent; Uscom was up 5.6 percent; Avita, Reva and Tissue Therapies rose more than two percent; with Circadian up 1.1 percent.

Cellmid led the falls, down 0.2 cents or 11.1 percent to 1.6 cents, with 2.7 million shares traded, followed by Antisense down 10.5 percent to 1.7 cents with 4.6 million shares traded and Phosphagenics down 10.3 percent to 13 cents with 3.3 million shares traded,

Mesoblast lost 6.3 percent to \$5.76 with 1.5 million shares traded; Allied Health and QRX fell five percent or more; Impedimed, Nanosonics and Starpharma were down three percent or more; Pharmaxis shed 2.8 percent; with Alchemia, Acrux, Clinuvel, Cochlear, CSL, Resmed, Sirtex and Viralytics down more than one percent.

## [RESMED](#)

Resmed says it has launched its Narval CC mandibular repositioning device at last week's American Academy of Dental Sleep Medicine meeting.

Resmed said the Narval CC was developed in France and was "an alternative solution to patients for snoring and obstructive sleep apnoea".

The company said it acquired the Narval CC with the acquisition of the Lyon-based Laboratoires Narval in 2009.

Resmed said it added an additional therapy method to complement the positive airway pressure (PAP) devices, providing a broader range of products for snoring and obstructive sleep apnoea.

Resmed Americas president Michael Farrell said that "the gold-standard therapy for obstructive sleep apnoea is PAP therapy".

"However, we know that today some patients either refuse PAP treatment or fail to comply," Mr Farrell said.

"Narval CC provides an effective alternative for those untreated patients," Mr Farrell said.

He said that Resmed was the only positive airway pressure company "with a customized solution for non-compliant patients or patients who refuse PAP treatment".

Resmed said that the Narval CC maintained the lower jaw in a forward position with a patented optimized retention of the mandible, allowing natural movement of the jaw, increasing patient comfort and resulting in superior compliance and efficacy.

The company said that each device was custom-made for the dental anatomy of individual patients using computer-aided design and manufacturing.

Resmed fell four cents or 1.2 percent to \$3.19 with 4.3 million shares traded.

## [NUSEP](#)

Nusep says it will receive an undisclosed payment from Nxgen Pharmaceuticals settling the companies' legal dispute.

In 2009 Nusep was to become a vehicle for the backdoor listing of Nxgen, purveyors of the then widely advertised male sex performance drugs (BD: Mar 13, 2009).

Nusep chief operating officer Prakash Patel told Biotech Daily that Nxgen had agreed to pay legal and other costs relating to the listing but when it failed to complete, Nxgen had not paid the undisclosed amounts required.

Nusep was untraded at 2.8 cents.

## [HEALTHLINX](#)

Healthlinx says that Dr Stewart Washer and Dr John Chiplin resigned as non-executive directors on June 13, 2012.

Healthlinx said that Dr Washer resigned due to increasing other work commitments and Dr Chiplin has been appointed as chief executive officer of another company.

The company said that Dr Washer joined the board in March 2008 and Dr Chiplin joined in December 2010.

Healthlinx said it would assess its needs regarding non-executive directors.

Healthlinx chief executive officer Nick Gatsios continues as a director with chairman Prof Greg Rice and director John Evans.

Healthlinx was unchanged at 0.4 cents with 4.4 million shares traded.

### HEARTWARE INTERNATIONAL

Heartware says that Larry Knopf has been appointed company secretary formally taking over the role from David McIntyre (BD: Oct 28, 2011).

Heartware said that Mr Knopf was appointed company secretary on May 12, 2011 and was also senior vice-president and general counsel.

The company said that Mr McIntyre was company secretary from September 19, 2008.

Heartware was unchanged at \$2.47 with 13 (thirteen) shares traded.

### ATCOR MEDICAL

Atcor has requested a voluntary suspension to follow the trading halt it requested on June 12, pending an announcement "in relation to a potential capital raising" (BD: Jun 12, 2012).

Atcor last traded at nine cents.